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Summary A follow-up study of pulmonary function in two groups of patients with testicular cancer was
performed 6-12 years after treatment. Both groups, 47 patients in each, had undergone retroperitoneal lymph
node dissection (RPLND). Patients with pathological stage (ps) II had also received bleomycin (median
270 mg) and cisplatin (median 540 mg) in three or four courses which included vinblastine or etoposide.
Patients in ps I and II were similar with respect to age, general health, observation period, inspired oxygen
fraction (FiO2) and maximal arterial oxygen pressure (PO2) at RPLND, but four (8.2%) with psll disease
developed densities on chest X-ray during chemotherapy. At the long-term follow-up the groups were similar
with respect to physical exercise, smoking pattern, present drug treatment and history of cardiopulmonary
disease. In both groups forced vital capacity (FVC), forced expiratory volume in one second (FEVy), and
single breath transfer factor for carbon monoxide (TLCO) were within normal limits, and no difference was
found between the groups. The combined data for both groups showed that smoking was highly associated
with impairment in TLCO (P = 0.005), and smoking frequency was negatively correlated to TLCO
(P = 0.002). We conclude that 3-4 courses with bleomycin, cisplatin and etoposide/vinblastine in testicular
cancer patients do not lead to long-term impairment of pulmonary function.
The outlook for patients with metastatic germ cell testicular
cancer was dramatically improved by the introduction of
cisplatin (Einhorn & Donohue, 1977). A 12-year survival of
65% in disseminated disease has been reported with com-
bination chemotherapy based on cisplatin (Roth et al., 1988),
and a 5-year survival of 80% has been achieved with the
present third generation regimens (Einhorn, 1987). In stage II
with disease confined to the testis and abdominal glands a
cure rate as high as 98% has been achieved (Peckham, 1988).
The excellent treatment results have drawn attention to long-
term toxic effects of cancer chemotherapy (Hansen et al.,
1989; Gietema et al., 1992; Osanto et al., 1992; Craig et al.,
1992).
During the last 15 years cisplatin has been combined with
bleomycin in routine chemotherapy of germ cell cancer. The
most important toxic effects of bleomycin and cisplatin are
pulmonary fibrosis and renal tubular disorder, respectively.
The combination of the two drugs may increase the risk of
bleomycin-induced pneumonitis because renal insufficiency
induced by cisplatin reduces the urinary clearance of
bleomycin (van Barneveld et al., 1984).
In view of the growing experience with long-term sur-
vivors, we have studied the pulmonary function in patients
with germ cell testicular cancer 6-12 years after
chemotherapy based on bleomycin and cisplatin.
Patients and methods
Patients
Retroperitoneal lymph node dissection (RPLND) was carried
out in 141 patients with non-seminomatous testicular cancer
clinical stage (cs) I and IIA at our institution during the
years 1979-1986. Staging was performed according to the
Royal Marsden Classification (Peckham et al., 1979). The
operation revealed metastatic lymph node involvement in 77
patients whose disease was reclassified as pathological stage
(ps) IIA or B. According to our treatment strategy 42
patients received three and 35 patients four cycles of post-
operative chemotherapy with cisplatin and bleomycin in
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combination with vinblastine until 1983 and later in com-
bination with etoposide (Aass et al., 1990). The presence of
ps I precluded chemotherapy unless metastases occurred
later.
Bleomycin 30 mg in 500 ml isotonic saline was given once
weekly as a 30 min IV infusion to a planned cumulative dose
of 270-300 mg. Every three weeks cisplatin 20 mg m2 was
given as a 4 h IV infusion in five consecutive days to a
cumulative dose of 300-400mgm2 assisted by continuous
hydration with 3 1 saline per 24 h throughout the treatment
period. Metoclopramide 40 mg and dexamethasone 20 mg
were added daily to the saline as antiemetic treatment.
According to the National Population Register all but two
patients were alive at the time of our study. The two patients
had died earlier due to pancreatic cancer and myocardial
infarction, respectively. Eleven patients were excluded
because of emigration (four cases), off schedule
chemotherapy (two cases), sarcoidosis (one case), mental
retardation (one case), abdominal radiotherapy (one case),
development of cancer in the contralateral testis (one case),
and drop out for social reasons (one case). The remaining
128 patients were available for participation. Entry was stop-
ped after 114 consecutive patients due to fulfillment of statis-
tical requirements (see Statistics). Thus, 57 patients in ps I
(control group) and 57 patients in ps IIA or B (case group)
were invited to a follow-up visit 6-12 years after RPLND.
No relapse was seen among the control patients and none
received chemotherapy during follow-up.
Clinical variabtes
The medical records of each patient were reviewed with
special attention to perioperative care, chemotherapy com-
pliance, pulmonary symptoms, and chest X-rays. According
to our routine chest X-rays were taken before each treatment
course and four weeks after completed therapy. Chest X-ray
changes which appeared during chemotherapy or the follow-
ing month were judged as pulmonary toxicity if no other
explanation was found. At long-term follow-up all patients
went through clinical examination, chest X-ray and routine
blood tests.
In addition the patients completed a self-administered
questionnaire regarding physical condition, smoking habits,
neurovascular symptoms and intercurrent disease. The
patients were stratified as smokers and non-smokers. The
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smoking frequency and daily cigarette consumption were
registered.
Pulmonaryfunction variables
All measurements were performed with the Gould automated
system 2400 (Sensormedics BV, Bilthoven; the Netherlands).
Measured variables included forced vital capacity (FVC),
forced expiratory volume in 1 s (FEVI) and the single breath
transfer factor for carbon monoxide (TLCO). The patients
were told not to smoke within one hour prior to the tests.
Spirometric variables were recorded as the best of three
attempts. TLCO was recorded once by means of the single
breath holding method (Ogilvie et al., 1957) and carried out
according to the recommended guidelines (Cotes, 1983). No
correction for hemoglobin was done. All pulmonary function
values were expressed as percentage of predicted value.
Reference values were those of the European Community for
Coal and Steel (ECCS) (Quanjer et al., 1983).
Statistics
The necessary sample sizes for statistical comparison of the
control and case group were calculated according to Pocock's
equation (Pocock, 1983, pp. 123-141). At least 40 patients in
each group were needed to show a 10% difference in TLCO
with 5% statistical significance given a test power of 80%
and a population standard deviation of 10-15%. The atten-
dance rate should be at least 60% to meet the requirements
for size of study population. All statistical calculations were
performed with the MEDLOG software using Wilcoxon
Rank Sum Test, Chi-Square Test and Linear Regression
Analysis. Two-tailed P-values below 0.05 were considered
significant.
Ethics
The study was approved and carried out according to the
ethical rules of our institutions. Each patient was informed
about the test results, and appropriate medical care was
given to those who needed further attention.
Results
In total, 105 patients (92.1%) responded to the invitation to
an outpatient appointment, 102 (89.5%) returned a com-
pleted questionnaire, and 94 (82.5%) met in person. Two
patients were unable to meet due to acute unrelated disease,
and nine patients failed to attend because of inconvenience.
No reply was received from five patients in the case group
and six patients in the control group. These eleven patients
had been alive and well at 5 years follow-up with no signs of
pulmonary disease.
Forty-seven patients (82.5%) in the case group and 47
(82.5%) in the control group were interviewed. At the time of
treatment the two groups were comparable with respect to
age, physical status, observation period, inspired oxygen frac-
tion (FiO2) and maximal arterial oxygen pressure (PO2) dur-
ing RPLND, and treatment outcome (Table I). However,
RPLND tended to last longer in the case group, although
not significant (P = 0.06).
The average cumulative dose of bleomycin was 277.7 mg
(median 270 mg, range 240-360) and of cisplatin 645.4 mg
(median 600, range 400-880). Two patients received 340 and
360 mg bleomycin, respectively, due to individual dose
adjustments. The regimen was scheduled as three courses for
25 patients or four courses for 22 patients. In 14 patients
(29.8%) bleomycin had been discontinued prematurely with a
median deviation of 30mg (range 10-30) from the planned
dose. Early discontinuation was caused by various side effects
in 11 patients (Table II), and by administrative errors in
three patients. None of the patients developed pulmonary
symptoms during chemotherapy, although pleural thickening
and subpleural fibrosis emerged on chest X-rays in four
Table I Baseline characteristics (median and range)
Case Control
group group P-value
N 47 47
Age at diagnosis 27.8 28.1 ns
(14.9-60.3) (17.9-63.7)
Duration of RPLND 3.8 3.4 ns
(hours) (1.8-7.2) (1.7-7.7)
Max P02 at RPLND 19.2 19.1 ns
(kPa) (12.7-25.4) (14.2-25.4)
%FiO2 at RPLND 30 29 ns
(24-35) (20-37)
Months from RPLND 109 108 ns
(58-143) (80-143)
N = sample size. RPLND = retroperitoneal lymph node dissection.
P02 = arterial partial oxygen pressure. FiO2 = oxygen fraction of the
inhalation gas.
Table II Causes of prematurely terminated bleomycin treatment in
11 patients
Symptoms andfindings Number
Skin rash 3
Thrombocytopenia 3
Infection 2
Leukopenia 2
Fever I
Deep venous thrombosis 1
Oliguria 1
Subileus 1
patients (8.2%) during treatment with bleomycin.
At long-term follow-up the patient characteristics of the
two groups were similar with respect to present drug treat-
ment, history of cardiopulmonary disease, general anesthesia
during follow-up, and airway infection during the last six
weeks before testing (Table III). Level of physical exercise
and number of smokers were the same in the two groups
(Table III). There was no difference in daily cigarette con-
sumption between smokers in the case (median 15, range
1-20) and the control (median 15, range 2-25) groups. The
pulmonary function was within the normal range without
significant differences between the groups (Table IV). None
of the patients had anemia, and there was no significant
correlation between TLCO% and hemoglobin (correlation
coefficient = 0.071) by linear regression analysis.
We found no association between smoking and the test
results of FVC and FEV1. On the other hand, the median
Table III Patient characteristics at follow-up
Case group Control group
(n = 47) (n = 47) P-value
Smokers* 18 20 ns
Cardiopulmonary disease 2 3 ns
General anesthesia 8 5 ns
during follow-up
Regular exercise 35 26 ns
Recent airway infection 5 5 ns
Present drug treatment 12 6 ns
*Smokers are defined as persons who smoke regularly on a daily
or weekly basis.
Table IV Pulmonary function and hemoglobin (median and
range)
Case group Control group P-value
TLCO* 98 (61-132) 90 (59-148) ns
FVC* 104 (67-135) 100 (62-126) ns
FEVI* 96 (65-124) 95 (65-111) ns
Hb 14.7 (12.6-16.8) 14.5 (13.2-16.9) ns
*Percent of predicted. TLCO = single breath transfer factor for
carbon monoxide. FVC = forced vital capacity. FEVI = forced
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of smokers was 85% of the predicted value compared frequency in the case and control group underlines the low
% in non-smokers (P = 0.005). Frequency of cigarette selection bias.
ig was negatively correlated to TLCO (correlation In our study the pulmonary function was assessed by ient = - 0.49, P = 0.002) (Figure 1). In smokers there spirometry (FVC, FEVI) and the single breath holding
) difference in the decline in TLCO between the case method for diffusion capacity (TLCO). Both methods are
)ntrol group (P = 0.827). quick and easy to perform and possess low variability which
groups of patients with particularly poor pulmonary is desirable in an outpatient comparative study. TLCO has
n did not appear in either of the two groups. Car- proven superior to flow-volume measurements as indicator of
monary disease, chest X-ray pathology and subclinical pulmonary toxicity during bleomycin treatment
turely discontinued bleomycin treatment did not ex- (S0rensen et al., 1985). In fact, TLCO is the only test which
ow TLCO scores. Values of less than 80% were found has shown to predict pulmonary toxicity of bleomycin in a
frequently in the case group and in the control group prospective study (van Barneveld et al., 1987).
V), but occurred more frequently in patients who In an extended retrospective overview of bleomycin 4d sustained Raynaud-like symptoms (P = 0.009). monotherapy the incidence of drug-induced pneumonitis was
chest X-ray densities seen during treatment had shown to be 3-7% (Lehne & Lote, 1990). However, in a
d in two patients while sustained fibrosis was seen in prospective study of combination chemotherapy in advanced
her two at follow-up. Crackles on inspiration were germ cell malignancy, pulmonary toxicity has been reported
at auscultation in one of these patients. The combined in as many as 46% of the patients (Levi et al., 1988). Our
)r the case and control groups revealed development of retrospective review of acute pulmonary toxicity revealed
radiological pulmonary densities without clinical 8.2% of clinically silent changes on chest X-rays. A five-days
,ance in five patients during follow-up. split-course of cisplatin instead of one-day treatment,
vigorous hydration, and a total dose of bleomycin within
300 mg seems to be tolerated by lungs of young men with
sion testicular cancer.
Patients who have been treated with bleomycin are suscep-
verall attendance of 82.5% was far better than tible to pulmonary complications from general anesthesia for
ed. This reflects a profound motivation for follow-up at least one year after discontinuation of the drug treatment
nd a high degree of compliance among patients cured (Goldiner & Schweizer, 1979). Long duration of anesthesia
testicular cancer. Due to fulfillment of statistical and high inspiratory oxygen fraction increase the complica-
ments entry was stopped after 57 patients in each tion risk (Lehne & Lote, 1990). However, the vulnerability
By random selection 14 patients were excluded from does not increase if the preoperative pulmonary function is
dy, eleven in ps II and three in ps I. According to the within normal limits (Lamantia et al., 1984). We did not find
al Population Register and the hospital's files they any sustained ventilatory defects in stage II testicular cancer
11 alive and none had revealed radiological or clinical patients 6-12 years after chemotherapy, although general
if pulmonary disease during five years routine follow- anesthesia had been carried out during the post-RPLND
Ius, the case and control group should be representa- period in several patients, including two successful coronary
r the whole study population. The equal attendance by-pass operations.
The single factor that influenced the pulmonary function in
our patient population was smoking. Smokers had a
significant reduction of TLCO as compared to non-smokers,
30- and TLCO was negatively correlated to smoking frequency.
27- Low TLCO was highly correlated to smoking. The pul- 24- monary function seemed to be more influenced by smoking
21- than by previous chemotherapy.
Our results correspond with the recent findings of Osanto
18 and coworkers who report that chemotherapy-induced pul-
15- monary toxicity in patients with testicular cancer is reversible
12- (Osanto et al., 1992). However, these authors did not correct
9 : for smoking which has a significant impact on TLCO accord-
6- ing to our results. The negative effect of smoking on TLCO
3- has also been demonstrated by Hansen et al. (1989), who
'report a long-term sustained reduction in TLCO after
64 80 96 112 128 144 bleomycin treatment. However, their patients had received
TLCO(% relatively high doses of bleomycin (median 354 mg) com- pared to our patients (median 270 mg) which could account
1 TLCO correlates with the frequency of cigarette smok- for the difference.
Drrelation coefficient: r= -0.49, P = 0.002). We conclude that 3-4 courses of combination chemo-
therapy with bleomycin, cisplatin and etoposide/vinblastine
in testicular cancer patients does not lead to long-term
impairment of pulmonary function, provided that the
cumulative dose of bleomycin does not exceed 300 mg. The
only single factor that caused significant reduction in TLCO V TLCO in patients treated with or without bleomycin smoking.
Number ofpatients
TLCO% + bleomycin - bleomycin Total
<80 12 6 18
, 80 35 41 76
Total 47 47 94
P =0.1900 (ns).
The authors are grateful to the technical assistance of Else-
Margrethe Blix and Christin Hornmoen who carried out the pul-
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